CSIMarket
 



Armata Pharmaceuticals Inc   (ARMP)
Other Ticker:  
 
 



 

What are Armata Pharmaceuticals Inc's Business Segments?



Armata Pharmaceuticals Inc is a leading biotechnology company that specializes in developing and commercializing bacteriophage-based therapeutics for the treatment of serious bacterial infections. The company offers a range of innovative products and services in various segments of the pharmaceutical industry.

1. Bacteriophage Therapy:
Armata Pharmaceuticals focuses primarily on the development of bacteriophage-based therapies. Bacteriophages are viruses that specifically target and kill bacteria, offering a promising alternative to traditional antibiotics. Armata is at the forefront of harnessing the power of bacteriophages to develop novel treatments for drug-resistant bacterial infections.

2. Product Portfolio:
a) PhageBank': Armata's flagship product, PhageBank', is a compendium of carefully selected phage strains that have been extensively studied and characterized. PhageBank' contains a diverse collection of bacteriophages that target various bacteria, including multidrug-resistant strains. This product is designed to provide a ready-to-use solution for clinicians and hospitals, allowing them to quickly identify and administer appropriate bacteriophage therapies.

b) AP-SA01: Armata's lead investigational product, AP-SA01, specifically targets Staphylococcus aureus infections. This bacteriophage-based therapy is being developed to treat serious antibiotic-resistant infections caused by Methicillin-resistant Staphylococcus aureus (MRSA), a significant global healthcare challenge.

c) AP-PA02: Another promising product in Armata's pipeline, AP-PA02 is being developed to target Pseudomonas aeruginosa infections. Pseudomonas aeruginosa is a common and highly drug-resistant bacterium associated with various infections, making it an important target for innovative therapeutic interventions.

3. Research and Development:
Armata Pharmaceuticals invests extensively in research and development activities to expand its product pipeline and explore the therapeutic potential of bacteriophages. The company conducts rigorous preclinical and clinical studies to assess the safety and efficacy of its products. Their research focuses not only on developing novel treatments but also on optimizing and customizing existing bacteriophage therapies to maximize their effectiveness in combating drug-resistant infections.

4. Collaborations and Partnerships:
Armata Pharmaceuticals collaborates with renowned academic institutions, government agencies, and industry partners to strengthen its product development efforts. These collaborations facilitate knowledge exchange, access to resources, and accelerate the translation of scientific discoveries into potential solutions for patients.

5. Antibiotic Resistance Solutions:
In addition to developing bacteriophage-based therapies, Armata Pharmaceuticals actively contributes to combating antibiotic resistance. The company explores various strategies to tackle this global health crisis, including research on combination therapies with conventional antibiotics, discovering synergistic effects between phages and antibiotics, and exploring adjuvant approaches.

Overall, Armata Pharmaceuticals Inc's extensive segments, products, and services revolve around utilizing bacteriophage therapy to combat serious bacterial infections, particularly those caused by drug-resistant strains. The company's focus on research, development, and collaborations demonstrates its commitment to addressing unmet medical needs and advancing the field of bacteriophage-based therapeutics.
   

Armata Pharmaceuticals Inc Tax Rate Companies within the Biotechnology & Pharmaceuticals Industry


Business Segments Q4
Revenues
(in millions $)
Q4
Income
(in millions $)
(Dec 31 2023)
%
(Profit Margin)
Total 1.53 -19.85 -

Growth rates by Segment Q4
Y/Y Revenue
%
(Dec 31 2023)
Q/Q Revenue
%
Q4
Y/Y Income
%
(Dec 31 2023)
Q/Q Income
%
Total 45.39 % 24.73 % - -

To get more information on Armata Pharmaceuticals Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com